Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers

The Lancet Neurology

Volumn 12, Issue 2, 2013, Pages 207-216

  Jack, Clifford R ^a   Knopman, David S ^a   Jagust, William J ^b   Petersen, Ronald C ^a   Weiner, Michael W ^c   Aisen, Paul S ^d   Shaw, Leslie M ^e   Vemuri, Prashanthi ^a   Wiste, Heather J ^a   Weigand, Stephen D ^a   Lesnick, Timothy G ^a   Pankratz, Vernon S ^a   Donohue, Michael C ^d   Trojanowski, John Q ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN STEM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DISEASE COURSE; DISEASE SEVERITY; HUMAN; NEUROIMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION DISORDERS; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; TAU PROTEINS;

EID: 84872379077     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70291-0     Document Type: Note

References (120)

1. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64:343-349.
2. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
3. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007, 69:631-639.
4. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
5. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009, 8:619-627.
6. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
7. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31:1275-1283.
8. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
9. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009, 65:176-183.
10. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010, 6:221-229.
11. Dickerson BC, Wolk DA MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012, 78:84-90.
12. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293.
13. Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 2009, 132:2048-2057.
14. DeCarli C, Frisoni GB, Clark CM, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007, 64:108-115.
15. Grundman M, Sencakova D, Jack CR, et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002, 19:23-27.
16. Fleisher A, Grundman M, Jack CR, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005, 62:953-957.
17. Jack CR Jr. Measuring progression of AD with imaging: outcome measures for trials. International Conference on Alzheimer's Disease; Vienna, Austria; July 11-16, 2009. S1-03.
18. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
19. Strozyk D, Blennow K, White LR, Launer LJ CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
20. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009, 66:382-389.
21. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
22. Kantarci K, Yang C, Schneider JA, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2010, 33:878-885.
23. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011, 68:1404-1411.
24. Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011, 68:232-240.
25. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
26. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012, 69:98-106.
27. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009, 1:371-380.
28. Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000, 95:721-725.
29. Zarow C, Vinters HV, Ellis WG, et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol 2005, 57:896-903.
30. Jack CR, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
31. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008, 42:559-567.
32. Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol 2012, 11:868-877.
33. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008, 71:743-749.
34. Josephs KA, Whitwell JL, Ahmed Z, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008, 63:204-212.
35. DeCarli CS, Atack JR, Ball MJ, et al. Postmortem regional neurofibrillary tangle densities, but not senile plaque densities, are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease. Neurodegeneration 1992, 1:113-121.
36. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62:925-931.
37. Perrin RJ, Fagan AM, Holtzman DM Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
38. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
39. Jack CR, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
40. Jack CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
41. Hyman BT Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011, 68:1062-1064.
42. Fox NC, Scahill RI, Crum WR, Rossor MN Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999, 52:1687-1689.
43. Jack CR, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000, 55:484-489.
44. Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008, 64:388-401.
45. Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement 2012, 8:389-398.
46. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006, 5:828-834.
47. Jack CR, Weigand SD, Shiung MM, et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008, 70:1740-1752.
48. Stern Y Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20:S69-S74.
49. Nelson PT, Abner EL, Schmitt FA, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 2010, 20:66-79.
50. Jack CR, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011, 68:1526-1535.
51. Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011, 68:1257-1266.
52. Forster S, Grimmer T, Miederer I, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2012, 71:792-797.
53. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitutdinal cognitive decline. Ann Neurol 2012, 72:578-586. for the Alzheimer's Disease Neuroimaging Initiative.
54. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804. for the Dominantly Inherited Alzheimer Network.
55. Chen K, Quiroz Y, Jakimovich L, et al. Age-associated trajectories of biomarkers in early-onset Alzheimer's disease, for the Alzheimer's Prevention Initiative. Alzheimer's Association International Conference; Vancouver, Canada; July 14-19, 2012. Abstract 01-01-04.
56. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
57. Caroli A, Frisoni GB The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 2010, 31:1263-1274.
58. Sabuncu MR, Desikan RS, Sepulcre J, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol 2011, 68:1040-1048.
59. Schuff N, Tosun D, Insel PS, et al. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging 2012, 33:845-855.
60. Jack CR, Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 2012, 69:856-867.
61. Jack CR Jr, Wiste HJ, Lesnick T, et al. Brain beta amyloid load approaches a plateau. Neurology (in press).
62. Thurfjell L, Lundqvist R, Villemagne VL, Rowe CC. A data-derived Aβ biomarker model computed using longitudinal PiB data from AIBL. Alzheimer's Association International Conference; Vancouver, Canada; July 14-19, 2012. Abstract 03-12-01.
63. Sonnen JA, Santa Cruz K, Hemmy LS, et al. Ecology of the aging human brain. Arch Neurol 2011, 68:1049-1056.
64. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 2008, 64:168-176.
65. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009, 66:200-208.
66. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006, 63:38-46.
67. White L Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis 2009, 18:713-725.
68. Toledo JB, Brettschneider J, Grossman M, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 2012, 124:23-35.
69. Jack CR, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measure and magnetic resonance imaging atophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133:3336-3348.
70. Klunk WE, Cohen A, Bi W, et al. Why we need two cutoffs for amyloid-imaging: early versus Alzheimer's-like amyloid-positivity. Alzheimer's Association International Conference; Vancouver, Canada; July 14-19, 2012. Abstract 03-12-03.
71. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010, 67:353-364.
72. Stern Y Cognitive reserve. Neuropsychologia 2009, 47:2015-2028.
73. Vemuri P, Weigand SD, Przybelski SA, et al. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain 2011, 134:1479-1492.
74. Reed BR, Mungas D, Farias ST, et al. Measuring cognitive reserve based on the decomposition of episodic memory variance. Brain 2010, 133:2196-2209.
75. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 2008, 65:1467-1471.
76. Vemuri P, Lesnick T, Przybelski S, et al. Effect of lifestyle activities on AD biomarkers and cognition. Ann Neurol (in press).
77. Knopman DS, Jack CR, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
78. Bateman R. Dominantly inherited Alzheimer network clinical trials: a model for prevention trials. Alzheimer's Association International Conference; Paris, France; July 16-21, 2011. S680.
79. Donohue M, Aisen PS, Dartigues J, Jacqmin-Gadda H, Gamst A, Le Gogg M. Validating Alzheimer's pathological cascade by merging ADNI with PAQUID. Alzheimer's Assoication International Conference; Vancouver, Canada; July 14-19, 2012. Abstract 04-01-03.
80. Jedynak BM, Liu B, Lang A, et al. Sample size comparisons in ADNI: a case for the Alzheimer's disease progression scale. Alzheimer's Association International Conference; Vancouver, Canada; July 14-19, 2012. Abstract 04-01-06.
81. Mungas D, Jones R, Tommet D. Sequencing of CSF abeta and tau, brain structure and function, and cognition in Alzheimer's disease. American Academy of Neurology Annual Meeting; New Orleans, LA; April 21-28, 2012. PD1.0003.
82. Braak H, Braak E Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18:351-357.
83. Braak H, Del Tredici K The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011, 121:171-181.
84. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012, 7:e31302.
85. de Calignon A, Polydoro M, Suarez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
86. Hardy J, Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
87. Small SA, Duff K Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
88. Mesulam MM Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999, 24:521-529.
89. Duyckaerts C Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol 2011, 121:145-147.
90. Price JL, Morris JC Tangles and plaques in nondemented aging and " preclinical" Alzheimer's disease. Ann Neurol 1999, 45:358-368.
91. Musiek ES, Holtzman DM Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol 2012, 25:715-720.
92. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
93. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
94. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
95. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004, 101:284-289.
96. Scarmeas N, Habeck CG, Stern Y, Anderson KE APOE genotype and cerebral blood flow in healthy young individuals. JAMA 2003, 290:1581-1582.
97. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010, 67:122-131.
98. Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010, 67:308-316.
99. Bu G Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009, 10:333-344.
100. Dumanis SB, Tesoriero JA, Babus LW, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 2009, 29:15317-15322.
101. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005, 25:7709-7717.
102. Greicius MD, Srivastava G, Reiss AL, Menon V Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004, 101:4637-4642.
103. Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 2009, 29:1860-1873.
104. Jones DT, Machulda MM, Vemuri P, et al. Age-related changes in the default mode network are more advanced in Alzheimer disease. Neurology 2011, 77:1524-1531.
105. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD Neurodegenerative diseases target large-scale human brain networks. Neuron 2009, 62:42-52.
106. Mormino EC, Smiljic A, Hayenga AO, et al. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex 2011, 21:2399-2407.
107. Machulda MM, Jones DT, Vemuri P, et al. Effect of APOE e{open}4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol 2011, 68:1131-1136.
108. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
109. Sheline YI, Morris JC, Snyder AZ, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J Neurosci 2010, 30:17035-17040.
110. Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci USA 2009, 106:7209-7214.
111. Chhatwal J, Schultz A, Johnson K, et al. Disrupted functional connectivity in autosomal dominant Alzheimer's Disease: preliminary findings from the DIAN study. Alzheimer's Association International Conference; Vancouver, Canada; July 14-19, 2012. Abstract 02-06-01.
112. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 2011, 14:750-756.
113. Jagust WJ, Mormino EC Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends Cogn Sci 2011, 15:520-526.
114. Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134:1089-1100.
115. Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012, 79:897-905.
116. Whitwell JL, Przybelski SA, Weigand SD, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130:1777-1786.
117. Vemuri P, Gunter JL, Senjem ML, et al. Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008, 39:1186-1197.
118. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238.
119. Villain N, Fouquet M, Baron JC, et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain 2010, 133:3301-3314.
120. Chetelat G, Villemagne VL, Pike KE, et al. Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis 2012, 10:141-144.